Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
25. Februar 2025 08:30 ET
|
Silexion Therapeutics Corp
Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
American Oncology Network Launches Cloud-Based Laboratory Information System to Streamline Pathology Reporting for Oncologists
25. Februar 2025 08:00 ET
|
American Oncology Network
American Oncology Network Launches Cloud-Based Laboratory Information System to Streamline Pathology Reporting for Oncologists
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
25. Februar 2025 07:00 ET
|
Marker Therapeutics
HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
25. Februar 2025 07:00 ET
|
Medicenna Therapeutics Corp.
MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a...
Revolution Medicines to Participate in March 2025 Investor Conferences
24. Februar 2025 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with...
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
24. Februar 2025 08:00 ET
|
Allarity Therapeutics, Inc.
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
19. Februar 2025 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
19. Februar 2025 07:05 ET
|
Boehringer Ingelheim Limited
Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small...
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
18. Februar 2025 07:00 ET
|
Purple Biotech Ltd.
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab...
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
16. Februar 2025 07:06 ET
|
Bahrain Oncology Center
MANAMA, Kingdom of Bahrain, Feb. 16, 2025 (GLOBE NEWSWIRE) -- The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient...